New Benzodihydrofuran Derivatives Alter the Amyloid β Peptide Aggregation: Strategies To Develop New Anti-Alzheimer Drugs.

Alzheimer's disease is a neurodegenerative disorder that is the leading cause of dementia in elderly patients. Amyloid-β peptide (1-42 oligomers) has been identified as a neurotoxic factor, triggering many neuropathologic events. In this study, 15 chalcones were synthesized employing the Claisen-Schmidt condensation reaction, starting from a compound derived from fomannoxine, a natural benzodihydrofuran whose neuroprotective activity has been proven and reported, and methyl aromatic ketones with diverse patterns of halogenated substitution. As a result, chalcones were obtained, with good to excellent reaction yields from 50 to 98%. Cytotoxicity of the compounds was assessed, and their cytoprotective effect against the toxicity associated with Aβ was evaluated on PC-12 cells. Out of the 15 chalcones obtained, only the 4-bromo substituted was cytotoxic at most tested concentrations. Three synthesized chalcones showed a cytoprotective effect against Aβ toxicity (over 37%). The 2,4,5-trifluoro substituted chalcone was the most promising series since it showed a cytoprotective impact with more than 60 ± 5% of recovery of cellular viability; however, 3-fluoro substituted compound also exhibited important values of recovery (50 ± 6%). The fluorine substitution pattern was shown to be more effective for cytoprotective activity. Specifically, substitution with fluorine in the 3,5-positions turned out to be particularly effective for cytoprotection. Furthermore, fluorinated compounds inhibited the aggregation rate of Aβ, suggesting a dual effect that can be the starting point of new molecules with therapeutic potential.

[1]  Ting Deng,et al.  The cellular model for Alzheimer's disease research: PC12 cells , 2023, Frontiers in Molecular Neuroscience.

[2]  G. Tang,et al.  New benzofuran neolignans with neuroprotective activity from Phyllanthodendron breynioides. , 2022, Natural product research.

[3]  S. Sadigh-Eteghad,et al.  Pharmacotherapy of Alzheimer’s disease: an overview of systematic reviews , 2022, European Journal of Clinical Pharmacology.

[4]  M. Chorilli,et al.  Insights for Alzheimer's disease pharmacotherapy and current clinical trials , 2022, Neurochemistry International.

[5]  Diogo Santos-Martins,et al.  AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings , 2021, J. Chem. Inf. Model..

[6]  M. Pinto,et al.  Chalcones as Promising Antitumor Agents by Targeting the p53 Pathway: An Overview and New Insights in Drug-Likeness , 2021, Molecules.

[7]  Yang Ouyang,et al.  Chalcone Derivatives: Role in Anticancer Therapy , 2021, Biomolecules.

[8]  W. Suo,et al.  Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease. , 2021, Bioorganic chemistry.

[9]  B. Salehi,et al.  Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence , 2021, Frontiers in Pharmacology.

[10]  P. Faller,et al.  Reproducibility Problems of Amyloid-β Self-Assembly and How to Deal With Them , 2021, Frontiers in Chemistry.

[11]  M. Arbitrio,et al.  The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease , 2021, Journal of central nervous system disease.

[12]  Y. Kim,et al.  Associations between metabolic syndrome and type of dementia: analysis based on the National Health Insurance Service database of Gangwon province in South Korea , 2020, Diabetology & Metabolic Syndrome.

[13]  Jevgenij A. Raskatov,et al.  Assessing Reproducibility in Amyloid β Research: Impact of Aβ Sources on Experimental Outcomes , 2020, Chembiochem : a European journal of chemical biology.

[14]  E. Barg,et al.  PC12 Cell Line: Cell Types, Coating of Culture Vessels, Differentiation and Other Culture Conditions , 2020, Cells.

[15]  M. Xiong,et al.  Shared Causal Paths underlying Alzheimer’s dementia and Type 2 Diabetes , 2020, Scientific Reports.

[16]  D. Broszczak,et al.  Oxidative stress in alzheimer's disease: A review on emergent natural polyphenolic therapeutics. , 2020, Complementary therapies in medicine.

[17]  J. Fuentealba,et al.  Exploring the Multi–Target Neuroprotective Chemical Space of Benzofuran Scaffolds: A New Strategy in Drug Development for Alzheimer’s Disease , 2020, Frontiers in Pharmacology.

[18]  G. Smith,et al.  The causes and consequences of Alzheimer’s disease: phenome-wide evidence from Mendelian randomization , 2019, Nature Communications.

[19]  H. Mori,et al.  Sustained Neurotrophin Release from Protein Nanoparticles Mediated by Matrix Metalloproteinases Induces the Alignment and Differentiation of Nerve Cells , 2019, Biomolecules.

[20]  F. Belluti,et al.  Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment. , 2019, European journal of medicinal chemistry.

[21]  D. Dickson,et al.  The neuropathological diagnosis of Alzheimer’s disease , 2019, Molecular Neurodegeneration.

[22]  C. Dobson,et al.  Secondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-β aggregates , 2019, Science Advances.

[23]  Francesca Seghetti,et al.  The Keap1/Nrf2-ARE Pathway as a Pharmacological Target for Chalcones , 2018, Molecules.

[24]  J. Marco-Contelles,et al.  Alzheimer's Disease, the "One-Molecule, One-Target" Paradigm, and the Multitarget Directed Ligand Approach. , 2018, ACS chemical neuroscience.

[25]  Xingmei Duan,et al.  Shikonin Protects PC12 Cells Against β-amyloid Peptide-Induced Cell Injury Through Antioxidant and Antiapoptotic Activities , 2018, Scientific Reports.

[26]  Eugene N. Muratov,et al.  Chalcone Derivatives: Promising Starting Points for Drug Design , 2017, Molecules.

[27]  C. Xing,et al.  Chalcone: A Privileged Structure in Medicinal Chemistry. , 2017, Chemical reviews.

[28]  L. Fershtat,et al.  Molecular Hybridization Tools in the Development of Furoxan‐Based NO‐Donor Prodrugs , 2017, ChemMedChem.

[29]  Wenhua Zheng,et al.  Artemisinin protects PC12 cells against β-amyloid-induced apoptosis through activation of the ERK1/2 signaling pathway , 2017, Redox biology.

[30]  Ying Peng,et al.  Bioactive Benzofuran Derivatives from Cortex Mori Radicis, and Their Neuroprotective and Analgesic Activities Mediated by mGluR1 , 2017, Molecules.

[31]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[32]  W. Geldenhuys,et al.  Pharmacotherapy of Alzheimer’s disease: current and future trends , 2015, Expert review of neurotherapeutics.

[33]  M. Kumar,et al.  Benzofuran–Chalcone Hybrids as Potential Multifunctional Agents against Alzheimer’s Disease: Synthesis and in vivo Studies with Transgenic Caenorhabditis elegans , 2014, ChemMedChem.

[34]  J. Wiltfang,et al.  Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease. , 2014, ACS chemical neuroscience.

[35]  A. Joerger,et al.  Principles and applications of halogen bonding in medicinal chemistry and chemical biology. , 2013, Journal of medicinal chemistry.

[36]  V. Andrisano,et al.  2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents. , 2012, European journal of medicinal chemistry.

[37]  Srikar Appalaraju,et al.  Microwave-Assisted Synthesis and Pharmacological Activity of Pyrazolyl Benzofuran Deravatives , 2012 .

[38]  Weiliang Zhu,et al.  Halogen bonding for rational drug design and new drug discovery , 2012, Expert opinion on drug discovery.

[39]  R. Ferrante,et al.  Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells. , 2012, Bioorganic & medicinal chemistry.

[40]  Suengmok Cho,et al.  Isoliquiritigenin, a chalcone compound, is a positive allosteric modulator of GABAA receptors and shows hypnotic effects. , 2011, Biochemical and biophysical research communications.

[41]  C. G. Mohan,et al.  Antiobesity and lipid lowering effects of Glycyrrhiza chalcones: experimental and computational studies. , 2011, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[42]  Marcelo Zaldini Hernandes,et al.  Halogen atoms in the modern medicinal chemistry: hints for the drug design. , 2010, Current drug targets.

[43]  Shinji Ohta,et al.  C-geranylated chalcones from the stems of Angelica keiskei with superoxide-scavenging activity. , 2008, Journal of natural products.

[44]  V. Andrisano,et al.  Benzofuran-based hybrid compounds for the inhibition of cholinesterase activity, beta amyloid aggregation, and abeta neurotoxicity. , 2008, Journal of medicinal chemistry.

[45]  E. Barreiro,et al.  Molecular hybridization: a useful tool in the design of new drug prototypes. , 2007, Current medicinal chemistry.

[46]  H. Kung,et al.  Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. , 2006, Journal of medicinal chemistry.

[47]  J. Barker,et al.  Development of an Ischemic Tolerance Model in a PC12 Cell Line , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[48]  J. Sikorski,et al.  Recent advances in therapeutic chalcones , 2004 .

[49]  Grégori Gerebtzoff,et al.  Halogenation of Drugs Enhances Membrane Binding and Permeation , 2004, Chembiochem : a European journal of chemical biology.

[50]  M. Kikuchi,et al.  Anti-allergic Activity of Naringenin Chalcone from a Tomato Skin Extract , 2004, Bioscience, biotechnology, and biochemistry.

[51]  A. D'Ursi,et al.  Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. , 2002, European journal of biochemistry.

[52]  J. Swatton,et al.  Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. , 1999, The Biochemical journal.

[53]  K. Beyreuther,et al.  Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. , 1995, European journal of biochemistry.

[54]  Manuela G. López,et al.  Chromaffin cells as a model to evaluate mechanisms of cell death and neuroprotective compounds , 2017, Pflügers Archiv - European Journal of Physiology.

[55]  D. Perl Neuropathology of Alzheimer's disease. , 2010, The Mount Sinai journal of medicine, New York.

[56]  C. Harrington,et al.  Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer’s disease , 1996, Acta Neuropathologica.

[57]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.